“Dr. Lipid” Thomas Dayspring, M.D. To Present During National Lipid Association Scientific Sessions In Las Vegas
Renowned lipidologist will discuss discordance in apoB and LDL-P study and interpretations for clinical practice
RICHMOND, Va., May 22, 2013 /PRNewswire/ — Dr. Thomas Dayspring, a Health Diagnostic Laboratory, Inc. Medical Advisory Board member known as “Dr. Lipid” in lipidology and Twitter circles, will give an oral presentation during a live session at the National Lipid Association’s Scientific Sessions 2013 on May 31 at 12 p.m. in Las Vegas. In addition, Dr. Dayspring – an NLA fellow – will be a guest on ReachMD.com Internet radio on June 1.
Dr. Dayspring’s poster presentation, High Proportion of Discordance Between ApoB and LDL-P in Clinical Practice is Associated with Insulin Resistance in More than 80,000 Individuals, is the result of a study from researchers at Health Diagnostic Laboratory, Inc. that found discordance between the two biomarkers is more widespread in routine clinical practice is than is currently recognized. The study found that one factor associated with the conflict appears to be insulin resistance. The study also notes that a more complete understanding of the phenomenon is needed to assist clinical interpretation.
In addition to Dr. Dayspring, HDL, Inc. researchers included Chief Laboratory Officer and company Co-founder Joseph P. McConnell, Ph.D.; Chief Scientific Officer and Co-founder G. Russell Warnick; Stephen A. Varvel, Ph.D. and director of clinical trials; and Chief Medical Officer Dr. Tara Dall. The study was co-sponsored by the Foundation for Health Improvement and Technology, an organization that serves as an online source for the most current and authoritative biomarker research available. Several HDL, Inc. researchers are also affiliated with FHIT.
“It is a great honor for the Foundation for Health Improvement and Technology to have our poster examining the discordance between two widely used biomarkers at Health Diagnostic Laboratory selected as one of three – out of the many submitted – chosen by the NLA referees,” said Dr. Dayspring, who has given more than 4,500 lectures in all 50 states on atherosclerotic heart disease and complex lipid disorders. “Our results will help clinicians make therapeutic decisions when they observe that these two normally correlative biomarkers are in disagreement.”
Dr. Dayspring, who tweets at @drlipid, will discuss the discordance abstract on ReachMD.com’s Lipid Luminations online radio program with Dr. Alan S. Brown, M.D., director of the Prevention Center/Lipid Clinic for Midwest Heart Specialists. The recording will be available for listening afterward at ReachMD.com/lipidluminations.
About Health Diagnostic Laboratory, Inc.
Health Diagnostic Laboratory, Inc. (HDL, Inc.) is a leader in health management offering a comprehensive test menu of risk factors and biomarkers for cardiovascular disease, diabetes, and related diseases. Our systematic approach identifies factors contributing to disease and provides a basis for effective treatment, allowing physicians to more effectively manage patients. As an added value, patients receive a personalized overview of their risk factors along with intensive counseling from expert Clinical Health Consultants at no additional cost, improving compliance and enhancing satisfaction. HDL, Inc. is a CLIA certified, CAP accredited laboratory. For more information, visit myhdl.com.
SOURCE HDL, Inc.